Xenon Pharmaceuticals drops 27.5% pre-market after suspending enrollment for depression drug trial
智通财经2026/09/18 08:26Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
Xenon Pharmaceuticals fell 27.5% in U.S. pre-market trading after the company suspended new patient enrollment in its depression drug trial.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
